Prevention, treatment of invasive fungal disease in allogeneic stem-cell transplantation recipients
the ONA take:
A team of researchers from Shanghai, China, hypothesized that prophylactic therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF) decreases invasive fungal disease (IFD) in patients undergoing allogeneic hematopoietic stem-cell transplantation (alloHSCT).
They compared once-daily subcutaneous GM-CSF (5 to 7 µg/kg per day), granulocyte colony-stimulating factor (G-CSF; 5 to 7 µg/kg per day), or a combination of G-CSF and GM-CSF (2 to 3 µg/kg per day each).
They randomly assigned 206 patients undergoing alloHSCT to one of the three treatments, which were started on day 5 after transplantation. Treatment was continued until the absolute neutrophil count was ≥1.5x109/L for 2 consecutive days.
The results showed no significant difference in 100-day incidences of proven and probable IFD among the three groups. In the GM-CSF and G-CSF+GM-CSF groups, 100-day cumulative mortality after transplantation and 100-day transplantation-related mortality were lower than in the G-CSF group.
IFD-related mortality was also lower in the GM-CSF and G-CSF+GM-CSF groups after 600 days follow-up, compared with the G-CSF group.
The researchers conclude that prophylactic GM-CSF improves 100-day transplantation-related mortality, 100-day cumulative mortality, and 600-day IFD-related mortality in recipients of alloHSCT, compared with G-CSF.
Prophylactic therapy with granulocyte-macrophage colony-stimulating factor may decrease invasive fungal disease.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Patients and Caregivers Worry About Cost of Cancer Care
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Seeking an Explanation for the Lack of Research Focused in Pediatric Oncology Therapeutics
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|